Aug 24, 2017
Pune, India, 24th August 2017: WiseGuyReports announced addition of new report, titled “Synovial Sarcoma - Pipeline Review, H2 2017”.
Pune, India - August 24, 2017 /MarketersMedia/ —
Summary
Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or spindle cell components. Symptoms include swelling, mass that may or may not be accompanied by pain and limping or difficulty using legs, arms, hands or feet. Treatment includes surgery, radiation therapy and chemotherapy.
GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/1927005-synovial-sarcoma-pipeline-review-h2-2017
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Synovial Sarcoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Synovial Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Synovial Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 7, 3 and 4 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Synovial Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Synovial Sarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Synovial Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Synovial Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Synovial Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Synovial Sarcoma (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Synovial Sarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Synovial Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Content: Key Points
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Synovial Sarcoma - Overview 6
Synovial Sarcoma - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 12
Synovial Sarcoma - Therapeutics Assessment 13
Assessment by Target 13
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Synovial Sarcoma - Companies Involved in Therapeutics Development 21
Adaptimmune Therapeutics Plc 21
Advenchen Laboratories LLC 21
EpiZyme Inc 22
Immune Design Corp 22
Immunocore Ltd 23
Johnson & Johnson 23
Karyopharm Therapeutics Inc 24
…Continued
ACCESS REPORT @ https://www.wiseguyreports.com/reports/1927005-synovial-sarcoma-pipeline-review-h2-2017
Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts
Contact Info:
Name: NORAH TRENT
Email: [email protected]
Organization: WISEGUY RESEARCH CONSULTANTS PVT LTD
Address: Office No. 528, Amanora Chambers Pune - 411028 Maharashtra, India
Phone: +44 208 133 9349
Source URL: http://marketersmedia.com/synovial-sarcoma-pharmaceutical-and-healthcare-pipeline-review-h2/232918
For more information, please visit http://www.wiseguyreports.com
Source: MarketersMedia
Release ID: 232918
The facility offers essential items for free, including clothes for babies and small children.
Households across Northern Ireland face increasing pressure on the cost of living as energy price hikes have come into effect.
The co-ordinated release is aimed at heading off further price spikes and avoiding a ban on US diesel exports.
The Trump administration again defended the decision to bar CNN, MS NOW and Politico from the White House and to exclude journalists from the pool that covers the president in small spaces.
The inquiry by the Commodity Futures Trading Commission centers on bets the former congressman made on Kalshi in the weeks before he was pardoned in January 2025.
The move followed reports detailing how A7, a Moscow firm, uses shell companies around the world to move funds for clients who are themselves subject to sanctions.
G20 trade ministers meet in Wisconsin amid trade tensions
Chinese manufacturers dominate Latin America's bus fleet
The discovery adds strong evidence that the outbreak that sickened thousands over the summer originated in a grower’s field or processing facility.
The artificial intelligence boom has pushed up the stock market, even as interest rates have pulled it down, our columnist says.
David Ellison, the tech scion who will run the combined company, borrowed the name of his original entertainment company that reflects his love of aviation. On Friday, the C.E.O.s of Warner Bros. were told they would not stay on once the companies merged.
The Group of 7, which includes Britain, France and Japan, announced the release of 100 million barrels over four months, effective immediately.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.